Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mensa

Showing results (701-710 of 792) with videos related to

Pageof 80
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-OldsLisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Health Research Policy and Systems|April 14, 2026
Political economy of adolescent mental health and well-being globallyOlivia Biermann, Yusra Ribhi Shawar, Jeremy Shiffman, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|October 25, 2022
Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?Anna Mensa-Vilaró, Asunción Vicente, Marta Español-Rego, et al.
Blood|December 30, 2017
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndromeDorota M Rowczenio, Shelly Pathak, Juan I Arostegui, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Infectious Diseases and Therapy|March 15, 2024
K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir ImpactCarolina Garcia-Vidal, Christian Teijón-Lumbreras, Tommaso Francesco Aiello, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2020
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studiesBetty B Yao, Linda M Fredrick, Gretja Schnell, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infectionD Viasus, P Puerta-Alcalde, C Cardozo, et al.
Pageof 80

Showing results (701-710 of 792) with videos related to

Sort By:
Pageof 80
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-OldsLisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Health Research Policy and Systems|April 14, 2026
Political economy of adolescent mental health and well-being globallyOlivia Biermann, Yusra Ribhi Shawar, Jeremy Shiffman, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|October 25, 2022
Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?Anna Mensa-Vilaró, Asunción Vicente, Marta Español-Rego, et al.
Blood|December 30, 2017
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndromeDorota M Rowczenio, Shelly Pathak, Juan I Arostegui, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Infectious Diseases and Therapy|March 15, 2024
K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir ImpactCarolina Garcia-Vidal, Christian Teijón-Lumbreras, Tommaso Francesco Aiello, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2020
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studiesBetty B Yao, Linda M Fredrick, Gretja Schnell, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infectionD Viasus, P Puerta-Alcalde, C Cardozo, et al.
Pageof 80